A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
← catalyst calendarNCT06541704 · readout in 712 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
975estimated
Sites
224
Countries
Australia, Austria, Canada +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-30 | actual | When the study began enrolling |
| Primary completion | 2028-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-04-09 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Age-related Macular Degeneration (AMD)
- Geographic Atrophy (GA)
Interventions
- Drug: Pozelimab — also filed as REGN3918
- Drug: Cemdisiran — also filed as ALN-CC5
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFGrowth rate (slope) of total GA lesion area (mm^2 /year) from baseline, measured by Fundus Autofluorescence (FAF)
measured To week 52
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed